,8 But some drug resistance is BCR-ABL independent, accounting for 50%,9 including CML stem cell-induced intrinsic resistance, which conveys a poor prognosis, and the basis of BCR-ABL-independent imatinib resistance is not understood. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.